Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: DrugBank:APRD00249 (Mutagen)
 5,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We treated 5 patients diagnosed with rheumatoid arthritis (RA) with nitrogen mustard (HN2) and monitored clinical and immunologic variables. HN2, 0.3 mg/kg ideal body weight was given over 7 days. Disease activity and immune function were monitored during and after treatment. Duration of morning stiffness (p = 0.0044), joint count (p = 0.0140), and assessment of pain (p = 0.0264) and function (p = 0.0057) improved by Day 6. T lymphocytes (p = 0.0060), especially T memory cells (CD4CD29; p = 0.0017) fell dramatically. HN2 is effective for rapidly gaining control of active RA. This effect is T cell specific.
 ...
PMID:Nitrogen mustard as induction therapy for rheumatoid arthritis: clinical and immunologic effects. 149 86

Some studies have assessed inflammatory cells such as macrophages, lymphocytes, and neutrophils in herniated lumbar disc tissues using histologic analysis. However, there is no consensus regarding the relationships between clinical symptoms, including radicular pain and the presence of inflammatory cells. It has been shown that autologous nucleus pulposus relocated on the lumbar nerve root in rats produces time dependent and reversible mechanical hyperalgesia, which is thought to be a pain related behavior in peripheral neuropathic pain models. The purpose of this study was to determine whether leukocytes play a role in the mechanical hyperalgesia induced by the nucleus pulposus and to characterize the role of leukocytes in radicular pain attributable to lumbar disc herniation. Nitrogen mustard was used to induce and evaluate leukocytopenia in rats. Sensitivity to mechanical noxious stimuli was measured quantitatively, and inflammatory cells in granulation tissue around the nerve root were examined histologically. The nucleus pulposus produced neither mechanical hyperalgesia nor abundant inflammatory cells in rats with nitrogen mustard induced leukocytopenia. Neuropathic pain produced by the nucleus pulposus, when placed on the nerve root, may be related to inflammatory cell infiltration induced by relocation of the nucleus pulposus, rather than the nucleus pulposus itself.
 ...
PMID:Role of leukocytes in radicular pain secondary to herniated nucleus pulposus. 1090 84

For former National Football League player Kerry Schmidt, BA,MBA, chronic pain is a part of everyday life. To repair sports-related trauma sustained during his 6-year career as a defensive back, Schmidt has undergone 24 major orthopedic surgeries over the past three decades and will undergo two or three additional procedures to repair his lower back. Now a sports reporter, a syndicated sports columnist, and a business owner, Schmidt says his pain at times has rated a 10-plus on a 10-point pain scale. Schmidt recently took control of his constant discomfort. After he consulted with Jack P. McNulty, MD,FACP, a specialist in the management of chronic pain, who collaborated with George B. Muller, RPh, a compounding pharmacist, Schmidt found relief with no adverse effects from the seldom-prescribed drug levorphanol.
...
PMID:Levorphanol, Methadone, and the Management of Intractable Chronic Pain: An Interview with Kerry Schmidt, BA,MBA; Jack P. McNulty, MD,FACP; and George B. Muller, RPh. 2397 21

Robert L Barkin talks to Roshaine Gunawardana, Commissioning Editor: Dr Barkin has authored over 150 publications including journals, book chapters and CD-Roms. He is a reviewer for over 30 journals, on the editorial board of nine journals and is an Associate Editor of the American Journal of Therapeutics. He received his BSc. Pharmacy degree from St Louis College of Pharmacy and Allied Science St Louis, MO, USA in 1963, an MBA in Healthcare Administration at DePaul University Chicago, IL, USA in 1976 and a doctorate in Clinical Pharmacy at Purdue University, IN, USA in 1985. Dr Barkin is engaged in a very active in-patient and out-patient practice with a collaborative arrangement with five anesthesiologist and consults with physical medicine and rehabilitation, rheumatology, oncology, neurology, neurosurgery, obstetrics and gynecology, psychiatry and chemical dependency/addiction specialists. He has presented over 500 formal lectures in the USA, Poland, India, China, Taiwan, Philippines, Puerto Rico, Australia and Canada. Dr Barkin's interest lies in pain, psychiatry, geriatrics, clinical pharmacology, clinical testing for medication and pain pharmacology. He has been the first to be granted scientific status with the American Academy of Pain Medicine.
Pain Manag 2012 Sep
PMID:Interview: The need to tailor pain management approaches to individual requirements. 2464 58

Chronic pain is common in individuals with HIV infection. The primary goal of treatment of chronic pain is not only to improve pain but also to improve physical and emotional function. Patients with chronic pain should be assessed for concurrent psychiatric and substance use disorders, as these conditions often coexist. Treatment of chronic pain may have limited success in the absence of treatment of psychiatric disorders. Treatments for chronic pain include nonopioid pharmacologic therapies and nonpharmacologic therapies (eg, cognitive and behavioral therapy, physical therapy), and the latter option is often the most effective for improving patient function. Care must be taken when initiating or continuing treatment with opioids, and the risks and benefits of treatment with opioids should be regularly assessed. This article summarizes a presentation by Jessica S. Merlin, MD, MBA, at the IAS-USA continuing education program held in New York, New York, in March 2015.
...
PMID:Chronic Pain in Patients With HIV Infection: What Clinicians Need To Know. 2651 96

The analgesic drug dipyrone is used to treat side effects (including pain and fever) of cancer chemotherapeutic agents. Dipyrone is metabolized to 4-aminoantipyrine (4-AA), a PGE2-dependent blocker and inhibitor of cyclooxygenase (COX). We evaluated the genotoxic, mutagenic, apoptotic, and immunomodulatory activities of 4-AA in vivo and the effects of its combination with the antineoplastic drugs doxorubicin, cisplatin, and cyclophosphamide. 4-AA did not cause genotoxic/mutagenic damage, splenic phagocytosis, or leukocyte alterations. However, when combined with the antineoplastic agents, 4-AA decreased their genotoxic, mutagenic, apoptotic, and phagocytic effects. These results suggest that 4-AA might interfere with DNA damage-mediated chemotherapy.
Mutat Res Genet Toxicol Environ Mutagen 2016 Jul
PMID:4-Aminoantipyrine reduces toxic and genotoxic effects of doxorubicin, cisplatin, and cyclophosphamide in male mice. 2740 79